RecruitingNCT04703699

Myval Global Study of Myval™ THV Series Implanted in Patients With Native Severe Aortic Valve Stenosis.

A Retrospective, Multinational, Multicentre, Observational Study in Patients Presenting With Native Severe Aortic Valve Stenosis and Treated With Myval™ Transcatheter Heart Valve Series in Real-world Setting.


Sponsor

Meril Life Sciences Pvt. Ltd.

Enrollment

200 participants

Start Date

Aug 7, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

A retrospective, multinational, multicentre, observational study in patients presenting with native severe aortic valve stenosis and treated with Myval™ Transcatheter Heart Valve Series in real-world setting.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • All patients of this study must have received Myval™ THV series for treatment of native severe aortic stenosis and completed a minimum of 30-day follow-up.

Exclusion Criteria1

  • No

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMyval Transcatheter Heart Valve Series

Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.


Locations(8)

North Estonia Medical center

Tallinn, Estonia

Clinical Institute Saint Ambrogio

Milan, Italy

Amphia Ziekenhui

Breda, North Brabant, Netherlands

University of Gdansk

Gdansk, Bażyńskiego, Poland

University Medical Centre Ljubljana

Ljubljana, Slovenia

Hospital Universitario de Gran Canaria Dr. Negrin

Las Palmas de Gran Canaria, Spain

Hospital Cliinico Univertistario de Valladolid

Valladolid, Spain

Kocaeli University School of Medicine

Kocaeli, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04703699


Related Trials